HighTide Therapeutics Inc. has announced the presentation of new clinical evidence demonstrating the potential renal benefits of its lead asset, HTD1801, in patients with mild renal impairment. The results were presented at the 58th Annual Meeting of the American Society of Nephrology (ASN) in Houston, US. HTD1801 is described as a first-in-class anti-inflammatory metabolic modulator with dual mechanisms of AMPK activation and NLRP3 inhibition, aimed at addressing residual risks associated with cardiovascular-kidney-metabolic diseases. Data supporting these findings were derived from two randomized, double-blind, placebo-controlled Phase III studies. The company notes that HTD1801 has received two Fast Track designations and one Orphan Drug designation from the US FDA. HighTide Therapeutics cautions that there is no guarantee HTD1801 will ultimately be successfully marketed.